Since the AURKA inhibitor alisertib can upregulate B7-H3 expression and modulate the immune microenvironment in glioma cells, thereby increasing response rate and clinical efficacy of B7-H3–specific blocking mAbs, we hypothesized that combining an AURKA inhibitor with an anti–B7-H3 mAb could improve GBM patient prognosis. Here, AURKA is linked to glioblastoma.